Rowasa and Uveitis - a phase IV clinical study of FDA data

Summary:

Uveitis is reported as a side effect among people who take Rowasa (mesalamine), especially for people who are female, 30-39 old, also take Levofloxacin, and have Acne.

The phase IV clinical study analyzes which people have Uveitis when taking Rowasa. It is created by eHealthMe based on reports of 930 people who have side effects when taking Rowasa from the FDA, and is updated regularly.

What is Rowasa?

Rowasa has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 943 Rowasa users. Check the latest studies of Rowasa.

What is Uveitis?

Uveitis (inflammation of the uvea) is found to be associated with 830 drugs and 1,529 conditions by eHealthMe. Check the latest studies of Uveitis.

On Jul, 26, 2026

930 people reported to have side effects when taking Rowasa.
Among them, 13 people (1.4%) have Uveitis.

Among these 13 people:

What is the gender of people who have Uveitis when taking Rowasa? *

female: 100 %
male: 0.0 %

What is the age of people who have Uveitis when taking Rowasa? *

What are other drugs people take besides Rowasa? *

What are other side effects people have besides Uveitis? *

Acute Kidney Failure: 11 people, 84.62%
Kidney Infection (Pyelonephritis): 11 people, 84.62%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 11 people, 84.62%
Generalized Anxiety Disorder (excessive, uncontrollable, unexplained and often irrational worry): 11 people, 84.62%
Inflammatory Bowel Disease: 11 people, 84.62%
Malignant Melanoma (skin cancer rises from melancytes): 11 people, 84.62%
Depression: 11 people, 84.62%
Muscle Aches (muscle pain): 10 people, 76.92%
Weakness: 9 people, 69.23%
Headache (pain in head): 9 people, 69.23%

What are the existing conditions these people have? *

Upper Respiratory Tract Infection: 11 people, 84.62%
Kidney Infection (Pyelonephritis): 11 people, 84.62%
Depression: 11 people, 84.62%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 11 people, 84.62%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 11 people, 84.62%
Acne (skin problems that cause pimples): 11 people, 84.62%
Pharyngitis (inflammation of the pharynx, causing a sore throat): 5 people, 38.46%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 1 person, 7.69%
Diarrhea: 1 person, 7.69%
Constipation: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Rowasa and have Uveitis?

- Check whether Uveitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rowasa:

Rowasa (943 reports)

Uveitis treatments and more:

Uveitis (29,545 reports)

Browse all side effects of Rowasa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Uveitis:

Uveitis (830 drugs)

Browse all the conditions that are associated with Uveitis:

Uveitis (1,529 conditions)

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Rowasa) and Rowasa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.